secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001558370-23-010485
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem reports 45% ORR for avutometinib+defactinib in RAMP 201 LGSOC trial
----------------------------------------------------------------------------

- Combination achieved 45% ORR (13/29 evaluable) and tumor shrinkage in 86% of heavily pretreated LGSOC patients.
- KRAS mutant subgroup ORR 60% (9/15); KRAS wild type ORR 29% (4/14); median response time 5.5 months.
- Safety profile consistent with prior data; discontinuation rate 12%, mostly due to elevated CPK (4.9%).
- FDA Breakthrough Therapy Designation previously granted; company plans filing for accelerated approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000155837023010485/0001558370-23-010485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000155837023010485/vstm-20230525x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer